Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach
DDX3 is an RNA helicase with oncogenic properties. The small molecule inhibitor RK-33 is designed to fit into the ATP binding cleft of DDX3 and hereby block its activity. RK-33 has shown potent activity in preclinical cancer models. However, the mechanism behind the antineoplastic activity of RK-33...
Main Authors: | Marise R. Heerma van Voss, Kai Kammers, Farhad Vesuna, Justin Brilliant, Yehudit Bergman, Saritha Tantravedi, Xinyan Wu, Robert N. Cole, Andrew Holland, Paul J. van Diest, Venu Raman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-06-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523318300561 |
Similar Items
-
Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33
by: Saritha Tantravedi, et al.
Published: (2019-01-01) -
Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer
by: Heerma van Voss MR, et al.
Published: (2017-07-01) -
Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells.
by: Mahendran Botlagunta, et al.
Published: (2011-03-01) -
Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer.
by: Guus M Bol, et al.
Published: (2013-01-01) -
Twist Modulates Breast Cancer Stem Cells by Transcriptional Regulation of CD24 Expression
by: Farhad Vesuna, et al.
Published: (2009-12-01)